Early Initiation of Antitumor Necrosis Factor Therapy Reduces Postoperative Recurrence of Crohn's Disease Following Ileocecal Resection.
Crohn’s disease
biologic therapy
postoperative recurrence
resection
Journal
Inflammatory bowel diseases
ISSN: 1536-4844
Titre abrégé: Inflamm Bowel Dis
Pays: England
ID NLM: 9508162
Informations de publication
Date de publication:
01 06 2023
01 06 2023
Historique:
received:
11
05
2022
medline:
2
6
2023
pubmed:
30
7
2022
entrez:
29
7
2022
Statut:
ppublish
Résumé
Postoperative recurrence (POR) of Crohn's disease (CD) is common after surgical resection. We aimed to compare biologic type and timing for preventing POR in adult CD patients after ileocecal resection (ICR). We performed a retrospective cohort study of CD patients who underwent an ICR at 2 medical centers. Recurrence was defined by endoscopy (≥ i2b Rutgeerts score) or radiography (active inflammation in neoterminal ileum) and stratified by type and timing of postoperative prophylactic biologic within 12 weeks following an ICR (none, tumor necrosis factor antagonists [anti-TNF], vedolizumab, and ustekinumab). We identified 1037 patients with CD who underwent an ICR. Of 278 (26%) who received postoperative prophylaxis, 80% were placed on an anti-TNF agent (n = 223) followed by ustekinumab (n = 28, 10%) and vedolizumab (n = 27, 10%). Prophylaxis was initiated in 35% within 4 weeks following an ICR and in 65% within 4 to 12 weeks. After adjusting for factors associated with POR, compared with no biologic prophylaxis, the initiation of an anti-TNF agent within 4 weeks following an ICR was associated with a reduction in POR (adjusted hazard ratio, 0.61; 95% CI, 0.40-0.93). Prophylaxis after 4 weeks following an ICR or with vedolizumab or ustekinumab was not associated with a reduction in POR compared with those who did not receive prophylaxis. Early initiation of an anti-TNF agent within 4 weeks following an ICR was associated with a reduction in POR. Vedolizumab or ustekinumab, at any time following surgery, was not associated with a reduction in POR, although sample size was limited. Postoperative recurrence of Crohn’s disease is common after ileocecal resection. In this dual-center study, early initiation of an anti-TNF agent within 4 weeks following an ileocecal resection was associated with a reduction in postoperative recurrence of Crohn’s disease.
Sections du résumé
BACKGROUND
Postoperative recurrence (POR) of Crohn's disease (CD) is common after surgical resection. We aimed to compare biologic type and timing for preventing POR in adult CD patients after ileocecal resection (ICR).
METHODS
We performed a retrospective cohort study of CD patients who underwent an ICR at 2 medical centers. Recurrence was defined by endoscopy (≥ i2b Rutgeerts score) or radiography (active inflammation in neoterminal ileum) and stratified by type and timing of postoperative prophylactic biologic within 12 weeks following an ICR (none, tumor necrosis factor antagonists [anti-TNF], vedolizumab, and ustekinumab).
RESULTS
We identified 1037 patients with CD who underwent an ICR. Of 278 (26%) who received postoperative prophylaxis, 80% were placed on an anti-TNF agent (n = 223) followed by ustekinumab (n = 28, 10%) and vedolizumab (n = 27, 10%). Prophylaxis was initiated in 35% within 4 weeks following an ICR and in 65% within 4 to 12 weeks. After adjusting for factors associated with POR, compared with no biologic prophylaxis, the initiation of an anti-TNF agent within 4 weeks following an ICR was associated with a reduction in POR (adjusted hazard ratio, 0.61; 95% CI, 0.40-0.93). Prophylaxis after 4 weeks following an ICR or with vedolizumab or ustekinumab was not associated with a reduction in POR compared with those who did not receive prophylaxis.
CONCLUSION
Early initiation of an anti-TNF agent within 4 weeks following an ICR was associated with a reduction in POR. Vedolizumab or ustekinumab, at any time following surgery, was not associated with a reduction in POR, although sample size was limited.
Postoperative recurrence of Crohn’s disease is common after ileocecal resection. In this dual-center study, early initiation of an anti-TNF agent within 4 weeks following an ileocecal resection was associated with a reduction in postoperative recurrence of Crohn’s disease.
Autres résumés
Type: plain-language-summary
(eng)
Postoperative recurrence of Crohn’s disease is common after ileocecal resection. In this dual-center study, early initiation of an anti-TNF agent within 4 weeks following an ileocecal resection was associated with a reduction in postoperative recurrence of Crohn’s disease.
Identifiants
pubmed: 35905032
pii: 6651946
doi: 10.1093/ibd/izac158
pmc: PMC10233395
doi:
Substances chimiques
Tumor Necrosis Factor Inhibitors
0
Ustekinumab
FU77B4U5Z0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
888-897Subventions
Organisme : NIDDK NIH HHS
ID : K23 DK124570
Pays : United States
Organisme : NIDDK NIH HHS
ID : K23 DK127157
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK123233
Pays : United States
Organisme : NIDDK NIH HHS
ID : K23DK127157
Pays : United States
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Inflamm Bowel Dis. 2016 Sep;22(9):2280-8
pubmed: 27508513
Aliment Pharmacol Ther. 2014 Jul;40(2):134-46
pubmed: 24912799
Am J Gastroenterol. 2001 Jul;96(7):2169-76
pubmed: 11467649
PLoS One. 2015 Dec 15;10(12):e0144900
pubmed: 26670274
Radiology. 2018 Mar;286(3):776-799
pubmed: 29319414
Lancet. 2015 Apr 11;385(9976):1406-17
pubmed: 25542620
Gastroenterol Clin North Am. 2012 Jun;41(2):303-14
pubmed: 22500519
Radiology. 2006 Feb;238(2):505-16
pubmed: 16436815
Inflamm Bowel Dis. 2012 Sep;18(9):1617-23
pubmed: 22081474
Gastroenterology. 2016 Jun;150(7):1568-1578
pubmed: 26946343
Gastroenterology. 2009 Feb;136(2):441-50.e1; quiz 716
pubmed: 19109962
United European Gastroenterol J. 2021 Jun;9(5):552-560
pubmed: 33951350
Gastroenterology. 1995 Jun;108(6):1617-21
pubmed: 7768364
Gastroenterology. 1990 Oct;99(4):956-63
pubmed: 2394349
Gastroenterology. 2008 Nov;135(5):1500-9
pubmed: 18823987
Clin Gastroenterol Hepatol. 2020 Oct;18(11):2518-2525.e1
pubmed: 31812654
J Crohns Colitis. 2013 Dec;7(12):e623-9
pubmed: 23810678
Gastrointest Endosc. 2019 Aug;90(2):269-275
pubmed: 30738034
Clin Gastroenterol Hepatol. 2014 Sep;12(9):1494-502.e1
pubmed: 24440221
Gastroenterology. 2013 Nov;145(5):996-1006
pubmed: 23896172
J Crohns Colitis. 2012 Oct;6(9):924-31
pubmed: 22424843
Gut. 1992 Mar;33(3):331-5
pubmed: 1568651
Am J Gastroenterol. 2013 Nov;108(11):1731-42
pubmed: 24019080
Inflamm Bowel Dis. 2018 Feb 15;24(3):502-509
pubmed: 29462385
Clin Gastroenterol Hepatol. 2022 Oct;20(10):2327-2336.e4
pubmed: 34968729
Lancet. 2017 Apr 29;389(10080):1741-1755
pubmed: 27914655
Gastroenterology. 1998 Feb;114(2):262-7
pubmed: 9453485
J Clin Gastroenterol. 2019 Jul;53(6):409-417
pubmed: 29517709
Am J Surg. 2014 Oct;208(4):591-6
pubmed: 25110291
Aliment Pharmacol Ther. 2015 Oct;42(7):867-79
pubmed: 26314275
Gastroenterology. 2017 Jan;152(1):271-275
pubmed: 27840074